Journal
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH
Volume 35, Issue 6, Pages 441-453Publisher
MARY ANN LIEBERT, INC
DOI: 10.1089/jir.2014.0168
Keywords
-
Funding
- Ministero dell'Istruzione, dell'Universita e della Ricerca-Progetti di Ricerca di Interesse Nazionale (MIUR-PRIN) [2012SNMJRL]
- University of Turin
- Innovative Biomedical Technologies (IBT) - Cariplo Foundation-Milan, Italy
Ask authors/readers for more resources
The nuclear interferon-inducible-16 (IFI16) protein acts as DNA sensor in inflammasome signaling and as viral restriction factor. Following Herpesvirus infection or UV-B treatment, IFI16 delocalizes from the nucleus to the cytoplasm and is eventually released into the extracellular milieu. Recently, our group has demonstrated the occurrence of IFI16 in sera of systemic-autoimmune patients that hampers biological activity of endothelia through high-affinity membrane binding. As a continuation, we studied the activity of endotoxin-free recombinant IFI16 (rIFI16) protein on primary endothelial cells. rIFI16 caused dose/time-dependent upregulation of IL-6, IL-8, CCL2, CCL5, CCL20, ICAM1, VCAM1, and TLR4, while secretion of IL-6 and IL-8 was amplified with lipopolysaccharide synergy. Overall, cytokine secretion was completely inhibited in MyD88-silenced cells and partially by TLR4-neutralizing antibodies. By screening downstream signaling pathways, we found that IFI16 activates p38, p44/42 MAP kinases, and NF-kB. In particular, activation of p38 is an early event required for subsequent p44/42 MAP kinases activity and cytokine induction indicating a key role of this kinase in IFI16 signaling. Altogether, our data conclude that extracellular IFI16 protein alone or by synergy with lipopolysaccharide acts like Damage-associated molecular patterns propagating Danger Signal through MyD88-dependent TLR-pathway.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available